	ProstateCancer – DrgDisAdr_BbsiProx_centre – nb – upSample				
				[DrgDis] Malignant neoplasm of prostate (C0376358)[DisGeNET_curat	
				[DrgDis] Adenocarcinoma of prostate (C0007112)[DisGeNET_curated]	
				[DrgDis] prostate adenocarcinoma (EFO_0000673)[OpenTargets_GA]	40
				[DrgDis] prostate carcinoma (EFO_0001663)[OpenTargets_GA]	20
				[DrgDis] prostate cancer (MONDO_0008315)[OpenTargets_GA]	0
				[DrgDis] prostate adenocarcinoma (EFO_0000673)[OpenTargets_RNA	\]
				[DrgDis] prostate carcinoma (EFO_0001663)[OpenTargets_RNA]	
				[DrgDis] prostate adenocarcinoma (EFO_0000673)[OpenTargets_litera	ature]
				[DrgDis] prostate carcinoma (EFO_0001663)[OpenTargets_literature]	
				[DrgDis] metastatic prostate cancer (EFO_0000196)[OpenTargets_liter	rature]
				[DrgDis] prostate cancer (MONDO_0008315)[OpenTargets_literature]	
				[DrgDis] Prostate Small Cell Carcinoma (EFO_1000499)[OpenTargets_	_literature]
				[DrgDis] Cancer of prostate GSE1413[Enrichr_GeoDiseaseSig_Up]	
				[DrgDis] Cancer of prostate GSE1413[Enrichr_GeoDiseaseSig_Down]	
				[DrgDis] Prostate adenocarcinoma (PRAD)[Intogen]	
				[DrgDis] Prostatic Neoplasms[PharmGKB_associated]	
				[DrgDis] Prostate carcinoma (EFO_0001663)[ThETA]	
				[DrgAdr] Adverse reaction (08.06.01.018) [ADReCS]	
				[DrgAdr] Poisoning (12.03.01.004) [ADReCS]	
				[DrgAdr] Neurotoxicity (12.03.01.011) [ADReCS]	
				[DrgAdr] Neurotoxicity Syndromes (MESH:D020258) [CTD]	
				[DrgAdr] Chemical and Drug Induced Liver Injury (MESH:D056486) [C	TD]
				[DrgAdr] Cardiotoxicity (MESH:D066126) [CTD]	
				[DrgAdr] Chemically–Induced Liver Toxicity (C4279912) [DisGeNET]	
				[DrgAdr] Cardiotoxicity (C0876994) [DisGeNET]	
				[DrgAdr] Drug toxicity (C0013221) [DisGeNET]	
				[DrgAdr] Neurotoxicity Syndromes (C0235032) [DisGeNET]	
Fold1	Fold2	Fold3	Fold4	Fold5	